Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with anlotinib and/or tegafur in elderly esophageal squamous cell carcinoma
ChiCTR2400087078Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: 1-year locoregional recurrence-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
anlotinibtegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400087078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087078.